Keep pulling the thread on Ester Baiget.
Novonesis views the $1 trillion specialty chemicals market as its total addressable market for replacing fossil-based solutions.
Novonesis's products typically represent 1% to 5% of the cost of goods sold for its customers' end products like detergents, bread, and biofuels.
Ester Baiget asserts that the full global adoption of existing biosolutions could reduce total planetary CO2 emissions by 8%.
Ester Baiget predicts that fully tapping the potential of current biosolutions could generate $800 billion in economic profit by 2035.
The newly merged company, Novonesis, operates with an EBIT margin of approximately 37%, an improvement from the legacy Novozymes' 25% margin.
Novonesis has shifted its pricing strategy from a 1-2% annual price erosion at legacy Novozymes to a 1-2% annual price increase that contributes to revenue growth.
Using AI, Novonesis has reduced the time to predict a protein's shape after an amino acid change from one year of lab work to less than a minute of computation.
Novonesis has developed market-ready enzymes that can break down PET plastic for infinite recycling with lower energy use.
The Norwegian Sovereign Wealth Fund owns 2.5% of Novonesis, an investment valued at over $700 million.
Novonesis's enzymes and microbes are used in products that reach over 2 billion people daily.
Novonesis maintains a library of over 100,000 microbial strains for its bioengineering and product development.
Novonesis is currently experiencing high single-digit revenue growth.